SCHEMBL5485422

SCHEMBL5485422

O=C(NCCCN1CCCCC1)c1cccc(Oc2cc(Cl)cc(Cl)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 10/20 0.59
DRD2 P14416 7/20 0.59
LMNA P02545 1/20 0.57
RAF1 P04049 1/20 0.54
SMYD2 Q9NRG4 1/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
MAPT P10636 1/20 0.51
PMP22 Q01453 1/20 0.51
CCR2 P41597 1/20 0.51
CCR3 P51677 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14430779 0.89 LMNA (0.70) DRD4DRD2LMNARAF1SMYD2
SCHEMBL5484126 0.88 ALDH1A1 (0.57) LMNAMEN1KMT2AL3MBTL1SLC6A2
SCHEMBL5475899 0.88 RAF1 (0.58) DRD4DRD2LMNARAF1SMYD2
SCHEMBL5474268 0.86 MCHR1 (0.56) DRD4DRD2LMNARAF1SMYD2
SCHEMBL5477335 0.86 DRD4 (0.66) DRD4DRD2SMYD2MAPTCCR3
SCHEMBL5476704 0.86 MCHR1 (0.58) DRD4DRD2LMNARAF1SMYD2
SCHEMBL5481493 0.85 LMNA (0.59) DRD4DRD2LMNARAF1SMYD2
SCHEMBL14430795 0.84 LMNA (0.58) DRD4DRD2LMNARAF1SMYD2
SCHEMBL5474859 0.84 MEN1 (0.61) DRD4DRD2SMYD2MEN1HPGD
SCHEMBL5481507 0.83 SCN9A (0.68) DRD4DRD2LMNARAF1SMYD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191358-A1 Novel piperidine derivative for the treatment of depression ASTRAZENECA AB (SE) 2007-08-16 US disclosed
US-20070191358-A1 Novel piperidine derivative for the treatment of depression ASTRAZENECA AB (SE) 2007-08-16 US disclosed
US-20070191358-A1 Novel piperidine derivative for the treatment of depression ASTRAZENECA AB (SE) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191358-A1 Novel piperidine derivative for the treatment of depression GRIN2C, TPH2, HTR5A DRD4 12/4885DRD2 5/4885LMNA 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.